SCHEMBL4788737

SCHEMBL4788737

Fc1cccc(C(Cc2ccccc2)NC2=NCCN2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NISCH Q9Y2I1 8/20 0.43
▸ MAOA P21397 6/20 0.41
▸ MAOB P27338 6/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ CYP1A2 P05177 2/20 0.40
▸ CYP2D6 P10635 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CNR2 P34972 1/20 0.38
▸ ADRA2A P08913 4/20 0.37
▸ ADRA2B P18089 3/20 0.37
▸ ADRA2C P18825 3/20 0.37
▸ ADRA1A P35348 2/20 0.37
▸ HTR7 P34969 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4788583 0.93 NISCH (0.43) NISCHMAOAMAOBKDM4EHTT
SCHEMBL949042 0.87 KDM4E (0.52) NISCHMAOAMAOBKDM4EHTT
Formic Acid SCHEMBL4748746 0.87 NISCH (0.38) NISCHKDM4EHTTNPSR1L3MBTL1
Iodide SCHEMBL951481 0.86 KDM4E (0.51) NISCHMAOAMAOBKDM4EHTT
SCHEMBL4114349 0.86 WDR5 (0.48) NISCHMAOAMAOBKDM4EHTT
SCHEMBL14042569 0.86 HTR1B (0.46) NISCHMAOAMAOBKDM4EHTT
SCHEMBL4787520 0.86 HTR1B (0.46) NISCHMAOAMAOBKDM4EHTT
SCHEMBL14042021 0.85 NISCH (0.43) NISCHMAOAMAOBKDM4EHTT
SCHEMBL4788949 0.85 ACP3 (0.45) NISCHMAOAMAOBKDM4EHTT
SCHEMBL4788335 0.81 CYP1A2 (0.48) NISCHMAOAMAOBKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008123821-A1 4, 5-DIHYDRO-LH-IMIDAZOL-2-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF RESPIRATORY, CARDIOVASCULAR, NEUROLOGICAL OR GASTROINTESTINAL DISORDERS ALBIREO AB (SE) 2008-10-16 — — WO disclosed
Send feedback